In the second half of 2022, China unveiled the details of its data export regulations, providing further explanations to its existing laws and regulations on data.
While there is no outright ban of cross-border data transfers, restrictions and procedures imposed on cross-border data transfers could create significant barriers for cross-border flow of data for legitimate business operations.
Such restrictions could potentially discourage companies from doing business in or with China, and eventually reduce the country’s trade competitiveness.
Since becoming effective in 2018, the European Union’s (EU) General Data Protection Regulation (GDPR) has been hailed as the gold standard in data protection. Perhaps surprising to many western observers, China’s Personal Information Protection Law borrowed many of the concepts and regulatory framework from GDPR.
However, despite the similarities in certain approaches between GDPR and Chinese data laws and regulations, China’s approach towards cross-border data flows is a significant departure from GDPR’s general principles endorsing free flow of data.
With restrictions on data flows, China faces challenges not only to its seat as the world’s factory, but also its digital economy champion status. Policies around cross-border data flows can tilt the balance in favour of China’s trade competitors such as Vietnam or Singapore.
Data has been playing a more important role in the future of manufacturing. Since 2020, more and more companies have started moving their supply chains beyond China to countries like Vietnam to diversify supply chain risk.
While Vietnam mandates the storage of data locally, transferring data outside Vietnam is not subject to requirements as strict as China. Vietnam endorses GDPR’s “adequacy of the level of protection” principle.
Reference:
https://www.weforum.org/agenda/2022/11/china-data-export-regulations-threaten-trade-competitiveness/
The global trade landscape is undergoing significant changes following the announcement of new reciprocal tariffs by the United States government. Recent developments indicate significant shifts in global trade dynamics, with key policy adjustments, ongoing negotiations, and evolving logistics patterns. Below is a summary of the latest developments.
In January 2025, the US FDA published a draft regulatory guidance entitled “The Considerations for Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products”.
The adoption of artificial intelligence (AI) and large language models (LLMs) is rapidly reshaping clinical research and drug development.
In the quest for increased sustainability, a lot has been made of the potential to use bio-based raw materials, captured CO2 and recycled plastics as raw materials for new chemicals. But what about using biotech processes to manufacture chemicals? Could it offer a more sustainable alternative to traditional petrochemical processing, and be more amenable to biobased raw materials?
High duties on imports from Canada, Mexico and China raise problems for international supply chains.
Advanced Drug Delivery Systems Market, valued at USD 234.84 billion in 2023, is on a trajectory of significant growth, projected to reach USD 352.01 billion by 2032
The U.S. Food and Drug Administration on January 15, 2025, announced its decision to ban Red Dye No. 3 also referred to as Erythrosine.
Targeted drug delivery revolutionises treatment by focusing medications on specific tissues, reducing the impact on healthy cells. Scientists enhance this precision with carriers like microspheres and nanoparticles, controlling release and absorption. Microspheres, made from biodegradable proteins or polymers, sustain drug release, making them ideal for targeted therapies, especially in oncology. Beyond drug delivery, microspheres open new possibilities across industries—from next-gen coatings to thermal insulation. With tailored sizes, shapes, and materials, they drive advancements in pharmaceuticals, advanced materials, and more.
The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing cosmetics for asbestos. The FDA noted that this move aims to protect consumers from potential harm posed by asbestos, a known carcinogen linked to serious illnesses such as lung and ovarian cancers.